Trial · NCT07898943
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients with any surgical site infection (SSI) | within 30 days after surgery | |
| Secondary | Proportion of patients with superficial SSI and deep SSI | within 30 days after surgery | |
| Secondary | Proportion of SSI among patients operated on for simple lumpectomy and for lumpectomy combined with a sentinel lymph node procedure | within 30 days after surgery | |
| Secondary | Proportion of SSI among patients with and without preoperative localisation of the tumour using a percutaneous device, such as metal wire | within 30 days after surgery | |
| Secondary | Proportion, type and severity of postoperative complications, according to the Clavien and Dindo classification, and the proportion of patients with postoperative sepsis or septic shock | within 30 days after surgery | |
| Secondary | The medical and/or surgical management of any SSI including outpatient/hospital management, local care alone or need for oral/parenteral curative antibiotic therapy, and/or need for revision surgery, need for additional scare or reopening, etc. | Management, even delayed, of any SSI occurring within 30 days after initial surgery | |
| Secondary | Proportion, type and severity (minor, moderate, severe, lethal) of intraoperative and postoperative adverse events potentially attributable to cefazolin or its placebo, and their causality according to the WHO scale | within 30 days after surgery | |
| Secondary | Duration of index hospital stay and whether the index stay had to be prolonged, notably due to the occurrence of a SSI | within 30 days after surgery | |
| Secondary | Need for an unexpected medical or surgical consultation or hospital readmission for a suspected or confirmed SSI | within 30 days after surgery | |
| Secondary | Need for an unexpected admission to the ICU | within 30 days after surgery | |
| Secondary | All-causes and septic-related mortality | within 30 days after surgery | |
| Secondary | The time (in days) to initiation of the adjuvant treatment (chemotherapy and/or radiotherapy, etc.) (if indicated by the attending oncologist) | Up to day 60 after surgery |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07898943/registered